+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
R

Actively Recruiting

This research aims to evaluate the clinical effectiveness, safety, and tolerability of XEN1101 when used alongside other antiseizure medications in adults with focal-onset seizures. It is a Phase 3, randomized, double-blind, placebo-controlled study involving approximately 360 participants. The study focuses on how XEN1101 affects seizure frequency compared to placebo while monitoring any side effects or safety concerns. Participants will be randomly assigned to one of three groups XEN1101 25 mg, XEN1101 15 mg, or placebo, taken once daily with an evening meal. The study includes a baseline period of up to 9.5 weeks to record seizure frequency, followed by 12 weeks of blinded treatment. After this, those who complete the treatment phase may join an open-label extension study for continued XEN1101 treatment, while others will enter an 8-week post-treatment follow-up period. During the study, participants will keep accurate seizure diaries and attend regular visits for assessments including seizure monitoring, safety checks, and tolerability evaluations. Researchers will measure the median percent change in focal seizure frequency from baseline through the 12-week treatment, along with other outcomes such as the proportion of participants experiencing significant seizure reduction and patient-reported global impressions. Safety is monitored from screening through 56 days after the final dose to ensure participant well-being throughout the trial.

Age: 18Years +All GendersPhase 3
103 locations
P

Actively Recruiting

Researchers are evaluating a new treatment called ramantamig-D for people newly diagnosed with multiple myeloma, a type of blood cancer affecting plasma cells. This study compares ramantamig-D with standard treatments that include combinations of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants who are not planned to undergo stem cell transplant as their first therapy. Participants will be randomly assigned to receive either ramantamig-D by subcutaneous injection or one of two standard treatment regimens chosen by their doctor DVRd daratumumab, bortezomib, lenalidomide, and dexamethasone or DRd daratumumab, lenalidomide, and dexamethasone. The study will measure how long participants live without their disease worsening and the percentage achieving a complete response with no detectable cancer cells up to 12 months. During the trial, participants will be monitored for progression-free survival for about 62 months and other outcomes like overall survival and quality of life for up to 100 months. Assessments will include disease response rates, adverse events, and patient-reported outcomes. Participants will have scheduled visits and evaluations to carefully track treatment effects and safety throughout the study.

Age: 18Years +All GendersPhase 3
103 locations
O

Actively Recruiting

Researchers are studying adult patients with unresectable or metastatic HER2-low and HER2-ultralow expressing breast cancer who have either received prior chemotherapy in the metastatic setting or have hormone receptor-positive disease not suitable for endocrine therapy. The study aims to observe the real-world use and effects of Trastuzumab deruxtecan T-DXd and conventional chemotherapy in these populations. This observational study collects data without administering any study drugs directly, focusing on patient characteristics, treatment patterns, and safety. Participants will be grouped into those receiving T-DXd according to approved medical guidelines and those treated with conventional chemotherapy, including drugs like capecitabine and paclitaxel. The study records treatment details and the management of any adverse reactions, with Group 2 patients contributing baseline data on conventional chemotherapy. Treatments are given as part of routine clinical care, following the Summary of Product Characteristics, without experimental interventions. During the study, participants treatment courses will be tracked for up to approximately 37 months. Researchers will evaluate the time to next treatment, treatment discontinuation, safety events, and patients impressions of treatment tolerability and quality of life. Data collection includes physician reports, patient diaries, and quality of life questionnaires. This long-term monitoring helps to understand treatment patterns and patient experiences in real-world settings.

Age: 18Years +All Genders
216 locations
S

Actively Recruiting

People with psychotic disorders like schizophrenia often face challenges in daily functioning, physical health, and quality of life. This study evaluates the feasibility and impact of a structured, multimodal physical exercise program for adults with psychosis who are treated with long-acting injectable antipsychotics. The goal is to see if supervised exercise can improve physical function, psychological well-being, and biological markers related to brain health and metabolism. Participants will be divided into two groups one receiving usual care and the other participating in a 24-week supervised exercise program. The exercise includes aerobic activities such as walking and cycling, strength training with exercises targeting different muscle groups, and mobility, balance, and flexibility exercises. Sessions are conducted by qualified professionals in an outpatient psychiatric setting in Portugal. Throughout the study, participants will undergo assessments at baseline, during the program, after completion, and at an 8-week follow-up. These assessments measure physical function, body composition, psychological well-being, quality of life, and blood markers like brain-derived neurotrophic factor, dopamine, serotonin, and metabolic indicators. The study aims to provide evidence for including exercise as part of routine psychiatric care for people with psychosis.

Age: 18Years +All GendersPhase Not Applicable
1 location
O

Actively Recruiting

Researchers are conducting a large, multi-country observational study called LIVER-R to collect real-world data on patients with hepatobiliary cancers, including unresectable hepatocellular carcinoma uHCC, advanced biliary tract cancer aBTC, and other related liver cancers. The study aims to evaluate the effectiveness of treatment regimens that include durvalumab-based therapies or other approaches used in routine clinical practice or early access programs. The study is descriptive and will analyze survival as well as other important clinical outcomes over time. Participants will be observed during their regular clinical care, with data collected both prospectively during visits and retrospectively from medical records, covering a baseline period of up to 5 years before treatment initiation. The study groups include patients receiving durvalumab-based regimens alone or in combination with local regional therapy LRT, as well as those treated with non-durvalumab therapies. Follow-up will continue for at least 2 years or until death, loss to follow-up, withdrawal, or study end. Throughout the study, researchers will gather information on survival rates, treatment duration, progression, recurrence, liver function, treatment patterns, adverse events requiring medical intervention, and patient and provider characteristics. Data will be collected at enrollment and every six months, with real-world overall survival as the primary measure. This extensive monitoring aims to provide a comprehensive view of treatment outcomes and patient experiences in real-world settings across multiple hepatobiliary cancer types.

Age: 18Years - 130YearsAll Genders
161 locations
P

Actively Recruiting

Peripheral arterial disease PAD mainly affects the lower limbs and reduces blood flow, causing symptoms like intermittent claudication, which involves pain and discomfort during exertion. This study evaluates a personalized multicomponent exercise program combining cardiovascular and resistance training to improve functional capacity in patients with PAD. Researchers aim to use artificial intelligence to analyze individual responses and tailor exercise doses accordingly. Participants will be randomly assigned to either a supervised exercise group or a usual care group. The exercise group will train three times a week for 12 weeks, with sessions lasting 60 to 80 minutes, including aerobic and resistance exercises personalized by pain response and muscle oxygen levels. The usual care group will receive lifestyle advice without a specific exercise program. The study uses wearable technology like near-infrared spectroscopy and accelerometry to monitor muscle oxygen saturation and movements in real time. Throughout the 12-week study, participants will undergo evaluations at the start and end, including measures of walking distances, muscle oxygenation, and muscle strength. Researchers will also assess blood pressure, quality of life, daily walking ability, glucose levels, and physical activity. The study tracks detailed physiological responses to exercise to understand and personalize treatment better. Participation involves regular supervised training sessions or lifestyle monitoring, with assessments to measure treatment effects and safety.

Age: 18Years +MALEPhase Not Applicable
3 locations
P

Actively Recruiting

Researchers are evaluating the use of teclistamab, both alone and in combination with lenalidomide, compared to lenalidomide alone as maintenance therapy in participants newly diagnosed with multiple myeloma following autologous stem cell transplant. This Phase 3, multicenter, randomized, open-label study aims to understand the benefits of these treatments in maintaining disease control after initial therapy. The study is sponsored by the European Myeloma Network B.V. and focuses on improving progression-free survival and disease response in this patient population. Participants are randomly assigned to one of three groups teclistamab combined with lenalidomide, lenalidomide alone, or teclistamab alone. Teclistamab is given as a subcutaneous injection, while lenalidomide is taken orally. The study treatment continues as maintenance therapy after the transplant. The trial compares the effects of these regimens over a long follow-up period, with assessments planned for up to 8 years. During the study, participants undergo regular evaluations including clinical exams, laboratory tests, and quality of life questionnaires such as the EORTC QLQ-C30 and MySIm-Q. Researchers monitor disease progression, survival, and treatment-related symptoms using patient-reported outcomes and clinical measures. The primary outcomes are progression-free survival from randomization and the rate of minimal residual disease-negative complete response at 12 months. Safety and quality of life are also closely followed throughout the study duration.

Age: 18Years +All GendersPhase 3
212 locations
O

Actively Recruiting

Diffuse large B-cell lymphoma DLBCL is a fast-growing and uncommon cancer affecting certain immune cells, and it is the most common type of non-Hodgkin lymphoma. Follicular lymphoma FL is a slower-growing form of non-Hodgkin lymphoma. This research aims to evaluate how well the investigational drug epcoritamab works in adults with advanced DLBCL and FL in real-world medical settings. Participants will receive epcoritamab as prescribed by their doctors following local country guidelines. The study will include about 700 adults treated across roughly 80 sites in 12 to 20 countries. Treatment is given as subcutaneous injections, and the study observes participants over up to three years to gather effectiveness information. During the study, participants will continue their regular hospital or clinic visits as part of their usual care, without extra procedures or visits added by the trial. Researchers will monitor the percentage of participants who achieve an overall response to the treatment over approximately three years. The study is observational, meaning it follows patients receiving epcoritamab under normal clinical practice without altering their care.

Age: 18Years +All Genders
73 locations
P

Actively Recruiting

Researchers are evaluating treatments for advanced breast cancer that is hormone receptor HR-positive and HER2-low or ultralow, classified as non-luminal subtype by gene expression profiling PAM50. This phase II international study compares trastuzumab deruxtecan T-DXd with a physicians choice of CDK46 inhibitor plus endocrine therapy ET to see which better prolongs progression-free survival in these patients. Participants will be randomly assigned to receive either T-DXd at 5.4 mgkg body weight by intravenous infusion every 21 days or one of several CDK46 inhibitors palbociclib, ribociclib, or abemaciclib combined with an endocrine therapy fulvestrant, letrozole, anastrozole, or exemestane chosen by their doctor. Treatment will continue in 21-day cycles, and the study will assess outcomes over up to 25 months. During the study, participants will undergo regular assessments including imaging scans to evaluate tumor response and progression. Researchers will monitor progression-free survival, overall survival, response rates, quality of life, and safety through adverse event tracking. Follow-up and treatment adherence will be closely observed to understand the effects and tolerability of these therapies in this specific breast cancer subtype.

Age: 18Years +All GendersPhase 2
79 locations

1-10 of 13

1